Sign up
Pharma Capital

'All systems go' with ReNeuron Group Plc looking to treat first PISCES III patient shortly

Michael Hunt, chief financial officer at ReNeuron Group Plc (LON:RENE), tells Proactive's Andrew Scott a Phase IIb clinical trial of their potentially breakthrough CTX cell treatment for stroke will soon get underway in the US.

The first of a group of 110 patients taking part in PISCES III will be enrolled ‘shortly’.

Top-line data from the randomised, placebo-controlled study is expected in early 2020, having been previously penciled in for the end of 2019.


View full RENE profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.